In vitro formation of oxidatively-modified and reassembled human low-density lipoproteins: antioxidant effect of albumin.
In early atherogenesis, excess plasma lipoproteins accumulate into the arterial lesion-prone areas as modified and reassembled lipoproteins (MRLp) appearing mostly as lipid droplets and vesicles. In the present study we produced such MRLp, in a cell-free system, devoid of any component of extracellular matrix, by subjecting in vitro human low-density lipoproteins (LDL) to autoxidation or copper-induced oxidation, for up to 96 h. As visualized by negative staining electron microscopy, a large number of lipoprotein particles (Lp) were progressively transformed into aggregates (ALp), fused particles (FLp) and vesicles (VLp). These modifications were paralleled by peroxidation of the samples as revealed by chemical analysis of each MRLp fraction isolated by a three-step purification procedure. LDL peroxidation in the above conditions was inhibited by the presence of albumin as assessed by TBARS and lipid analysis, and by the lack of MRLp formation. This protective effect was independent of albumin source (bovine, human, rabbit) and occurs at an albumin/LDL ratio of 1 when Cu2+ was present, and at a ratio of 0.25 in autoxidative conditions. The results show that: (i) in vitro LDL autoxidation or copper-induced peroxidation in a cell-free system can generate modified and reassembled lipoproteins similar to those detected in vivo in the arterial intima at the inception of atherogenesis; (ii) Lp particles appear to be sequentially transformed in self-aggregates, droplets and vesicles; (iii) serum albumin can completely prevent these LDL alterations.
Dobrian
A
A
Institute of Cellular Biology and Pathology, Bucharest, Romania.
Mora
R
R
Simionescu
M
M
Simionescu
N
N
D000975:Antioxidants / Q000494:pharmacology*; D002474:Cell-Free System; D005591:Chemical Fractionation; D006801:Humans; D007136:Immunoglobulins / Q000494:pharmacology; D015227:Lipid Peroxidation; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000302:isolation & purification* / Q000648:ultrastructure; D010084:Oxidation-Reduction; D010316:Particle Size; D012709:Serum Albumin / Q000494:pharmacology*
D000975:Antioxidants; D007136:Immunoglobulins; D008077:Lipoproteins, LDL; D012709:Serum Albumin